MARKHAM, ON, Aug. 12 /PRNewswire-FirstCall/ - AlphaRx AlphaRx, a leader in the development of Nanotechnology for Drug Delivery Platforms, is pleased to announce that it has received conditional approval from the TSX Venture Exchange to list the common shares of the Company on the Exchange. Listing of the common shares on the TSX Venture Exchange is subject to compliance with all conditions of the Exchange, including receipt of all required documentation. AlphaRx intends to fulfill the listing conditions as soon as is practical.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
Copyright @ 2008. AlphaRx Inc.
CONTACT: AGORACOM Investor Relations Corp., Web: http://www.agoracom.com,